- Home
- MTN vs IONS Comparison
MTN vs IONS Comparison
Compare MTN & IONS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MTN
- IONS
- Stock Information
- Founded
- MTN 1997
- IONS 1989
- Country
- MTN United States
- IONS United States
- Employees
- MTN N/A
- IONS N/A
- Industry
- MTN Services-Misc. Amusement & Recreation
- IONS Biotechnology: Pharmaceutical Preparations
- Sector
- MTN Consumer Discretionary
- IONS Health Care
- Exchange
- MTN Nasdaq
- IONS Nasdaq
- Market Cap
- MTN 7.1B
- IONS 6.0B
- IPO Year
- MTN 1997
- IONS 1991
- Fundamental
- Price
- MTN $184.48
- IONS $36.17
- Analyst Decision
- MTN Hold
- IONS Buy
- Analyst Count
- MTN 10
- IONS 18
- Target Price
- MTN $205.30
- IONS $62.00
- AVG Volume (30 Days)
- MTN 666.6K
- IONS 1.7M
- Earning Date
- MTN 12-09-2024
- IONS 02-19-2025
- Dividend Yield
- MTN 4.82%
- IONS N/A
- EPS Growth
- MTN 5.26
- IONS N/A
- EPS
- MTN 6.16
- IONS N/A
- Revenue
- MTN $2,886,901,000.00
- IONS $803,067,000.00
- Revenue This Year
- MTN $5.61
- IONS N/A
- Revenue Next Year
- MTN $4.33
- IONS $19.61
- P/E Ratio
- MTN $29.90
- IONS N/A
- Revenue Growth
- MTN 0.64
- IONS 30.57
- 52 Week Low
- MTN $165.00
- IONS $33.33
- 52 Week High
- MTN $236.92
- IONS $54.44
- Technical
- Relative Strength Index (RSI)
- MTN 49.81
- IONS 41.84
- Support Level
- MTN $187.99
- IONS $36.39
- Resistance Level
- MTN $194.47
- IONS $38.90
- Average True Range (ATR)
- MTN 6.51
- IONS 1.52
- MACD
- MTN -1.21
- IONS -0.08
- Stochastic Oscillator
- MTN 41.25
- IONS 6.61
About MTN Vail Resorts Inc.
Vail Resorts Inc Bhd is a resorts and casinos company that operates mountain resorts and ski areas. The company has three business segments that include Mountain, Lodging, and Real Estate. The Mountain segment operates numerous ski resort properties that offer a variety of winter and summer activities, such as skiing, snowboarding, snowshoeing, hiking, and mountain biking. The Lodging segment owns and operates hotels and condominiums. The Real Estate segment owns, develops, and leases real estate, typically near its other properties. The company generates the vast majority of its revenue within the United States.
About IONS Ionis Pharmaceuticals Inc.
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and partner Biogen brought Spinraza to market in 2016 as a treatment for a rare neuromuscular disorder, spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024.